Benitrobenrazide, an innovative selective HK2 inhibitor, demonstrates the capability to target the binding site and preclude glucose association with HK2, thus efficaciously inhibiting pancreatic cancer growth by disrupting glycolytic pathways.146. The gene discussed is HK2; the disease is pancreatic neoplasm.